Long-term daily aspirin helps prevent hereditary colorectal cancer

Dp5

Long-term follow-up of the CAPP2 study demonstrates the benefits of daily aspirin for preventing hereditary colorectal cancer (Lynch syndrome)  CAPP2 is an international, double-blind, randomised, placebo-controlled registry-based study of cancer prevention in people with Lynch syndrome. Lynch syndrome is a hereditary genetic condition which increases the person’s risk of developing certain cancers. The 10 year […]

Meta-analysis concludes that monotherapy with low-dose aspirin is comparable with P2Y12 inhibitor monotherapy for the secondary prevention of cardiovascular disease -confirming aspirin’s place as a cost effect drug of choice.

Dp2

Chiarito and colleagues conducted a systematic review and meta-analysis of all randomised trials that compare P2Y12 inhibitors with low-dose aspirin monotherapy for the prevention of secondary cardiovascular (CV) events in patients with established cerebrovascular, coronary or peripheral artery disease with the aim of finding the optimal regimen. The researchers found nine trials with a total […]

Pioneering low-dose aspirin research group to receive Senior Science Award 2020

Awards

The scientists responsible for first trials of low-dose daily aspirin to prevent coronary and cerebrovascular events have been recognised with the International Aspirin Foundation’s Senior Science Award 2020. Professors Lars Wallentin, Jan van Gijn, Bo Norrving and Tom Meade led four pivotal trials across Sweden, the Netherlands and the UK in the 1980s. Together, these […]